E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with Type 2 diabetes mellitus |
|
E.1.1.1 | Medical condition in easily understood language |
Patients diagnosted with diabetes mellitus typ 2 to improve glycaemic control when diet and exercise alone do not provide adequate control |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Effect of empagliflozin 10 mg once daily on cardiac output in comparison to placebo after 1 day, 3 days and 12 weeks of treatment (measured with a noninvasive monitoring [ClearSight System]). |
Die Wirkung der Behandlung mit Empagliflozin 10 mg einmal täglich gegenüber Placebo auf auf den systemischen Gefäßwiderstand und das Herzzeitvolumen bei Patienten mit Typ-2-Diabetes . |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Type 2 diabetes 2. Serum levels of HbA1c ≥ 6.5 % 3. Age ≥ 18 years 4. Written informed consent prior to study participation 5. Participants of child-bearing age should use adequate contraception |
|
E.4 | Principal exclusion criteria |
1. Type 1 diabetes 2. Systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 100 mmHg 3. Age ≥ 75 years 4. Pregnancy and lactating females. 5. Renal impairment (GFR < 30 ml/min/1.73 m2) 6. Liver disease (serum levels of AST, ALT or AP more than three times the upper limit of normal) 7. Uncontrolled thyroid disease 8. Endocrinopathies like Graves’ disease, acromegaly, Cushing’s disease 9. Hypertensive retinopathy or encephalopathy 10. Acute coronary syndrome, stroke or transient ischemic attack in last 6 weeks prior to randomization 11. The subject is mentally or legally incapacitated 12. The subject received an investigational drug within 30 days prior to inclusion into this study 13. Urinary tract infections or significant formation of residual urine in medical history
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Effect of Empagliflozin 10 mg once daily on systemic vascular resistance in comparison to placebo after day 1, day 3 and 12 weeks of treatment (measured with a noninvasive monitoring [ClearSight System]) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
day 1, day 3 and 12 weeks |
|
E.5.2 | Secondary end point(s) |
Most important secondary analysis: - Stroke volume (SV) - Stroke volume variation (SVV) - Resting energy expenditure (REE) (measured by indirect calorimetry [CardioCoach CO2]) - respiratory exchange rate (RER) measured by indirect calorimetry [CardioCoach CO2]) - Blood pressure - Sodium excretion in 24 h urine collection (osmolarity, sodium, potassium, creatine, chloride, creatine-clearance, protein, urea nitrogen, magnesium, phosphate, glucose, calcium, uric acid) - Body weight - Heart rate - NT-proBNP and cystatin C - Serum levels of chloride, glucose, HbA1c, glucagon, insulin, total-ketone bodies, β-hydroxybutyrate, aldosterone and free fatty acid - Serum osmolarity - Change in left ventricular function between baseline and after 12 weeks as determined by 2D and 3D parameter global Strain Rate E - Change in left ventricular diastolic function between baseline and after 12 weeks as determined by standardized parameter E/é and left atrial (LA) volume - Change in left ventricular systolic function by ejection fraction (EF)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
day 1, day 3 and 12 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |